After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

The lead author of a recent trial that led to an FDA notification of potential issues with bioprosthetic aortic valves reiterated that the findings related to neurologic events were preliminary and inconclusive.

A randomized trial found that patients with diabetes and coronary artery disease who underwent PCI and received paclitaxel-eluting stents had a significantly higher 1-year rate of the primary outcome of target-vessel failure compared with patients who received everolimus-eluting stents.

After a year of follow-up, patients with STEMI who received thrombus aspiration during PCI had similar results in the primary outcome of cardiovascular death, recurrent MI, cardiogenic shock or class IV heart failure compared with patients undergoing PCI alone, according to a prospective, randomized trial.

Providing ranolazine to patients with chronic angina and incomplete revascularization after undergoing PCI did not reduce the composite end point of ischemia-driven revascularization or hospitalization without revascularization, according to a multicenter, randomized, double-blind, placebo-controlled study.

Hear what’s new from Meril's vice president, Sanjeev Bhatt, on tapered drug eluting stents, bioabsorbable scaffolds, dilatation catheters and TAVR.

More than a year’s worth of real world data in more than 6,000 patients showed that all-cause mortality rates and stroke at 30 days with Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system were comparable with findings in the pivotal trial that led to the device’s approval.

Patients undergoing PCI who received a second-generation drug-eluting absorbable metal scaffold had favorable angiographic and clinical outcomes after six months, according to the first in-man study of the device.